Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 1999

View Archived Issues

SmithKline Beecham: Annual Report 1998/Q1 Report 1999

Sepracor: Q1 1999 highlights

Positive results achieved in Alexion's phase I/II study of 5G1.1 in RA

Alcon to continue Lu-Tex development

Synthetic antitumor agent derived from Et 743 shows promise following preliminary testing

OraVax: Q4 and year-end 1998 highlights

Another series of HDL-increasing compounds revealed by American Home Products

FDA approves Roche's lipase inhibitor for marketing

Vertex and Glaxo Wellcome begin shipping new anti-HIV compound

Lorus to acquire GeneSense

New phenylpropionic acid derivatives with excellent antidiabetic effects

Vasodilating benzamide and cinnamide derivatives from China

China Pharmaceutical University develops effective antiarrhythmic agents

Genta and NCI to collaborate on G-3139 clinical development

Anti-CD11/CD18 MAb not effective in phase II trial in exacerbations of MS

Series from Takeda with neuroprotective effects

U.S. study now under way using artificial liver device incorporating human cells

RiboGene issued two patents related to translation-targeted drug discovery

Cellegy initiates phase II testing of Anogesic in hemorrhoid surgery patients

Urethra-selective alpha1-agonists under development at Mitsui for urinary incontinence

European CPMP emits positive opinion on Zeffix for chronic HBV

New cyclic compounds designed at JT reduce only elevated blood glucose levels

Amgen: Q1 1999 highlights

Dual-action antiatherosclerotic agents in the Sankyo pipeline

BRAINS results presented at American Academy of Neurology meeting

Therapeutic Antibodies: year-end 1998 highlights

Pregabalin: first clinical experience in patients with refractory complex partial seizures

Muscarinic agonists fail to improve cognitive function in AD

Noncompetitive AMPA antagonist potentiates levodopa activity in primate PD model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...